Therapeutic Monoclonal Antibodies Approved by FDA in 2022

Abstract

Compared with the annual record high, 17 therapeutic monoclonal antibodies (mAb) approved in 2017, this year total 16 therapeutic mAb were approved by FDA, interestingly 4 of them targeted at VEGF (Vascular Endothelial Growth Factor), two indicated for solid tumor, two for Neovascular (Wet) Age-Related Macular Degeneration [1]. Monoclonal antibody technique was created by Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975 by using a mouse x mouse hybridoma. In 1984 they were awarded the Nobel Prize in Medicine for the discovery. Eight years later, in 1992 US FDA approved the first therapeutic mAb muromonab